VWF and FVIII levels and VWFpp results
| . | VWF:Ag (IU/dL) . | VWF:Act (IU/dL) . | FVIII:C (IU/dL) . | GTi VWF:Ag (IU/dL) . | GTi VWFpp (IU/dL) . | GTi VWFpp:Ag† . | CRP (mg/L) . |
|---|---|---|---|---|---|---|---|
| Diagnosis | 4 | 7 | 2 | <1 | 202 | >202 | 31 |
| RM1 | 147 | 135 | 92 | 116 | 227 | 1.96 | 6.9 |
| RL1 | <10 | <10 | 3 | <1 | 105 | >105 | 27 |
| Pre-DDAVP* | <10 | <10 | 5 | <1 | 129 | >129 | — |
| 1 hour post-DDAVP* | <10 | <10 | 7 | <1 | 172 | >172 | — |
| CR | 97 | 129 | 128 | 90 | 118 | 1.3 | 3.0 |
| NPP | — | — | — | 119 | 100 | 0.8 | — |
| . | VWF:Ag (IU/dL) . | VWF:Act (IU/dL) . | FVIII:C (IU/dL) . | GTi VWF:Ag (IU/dL) . | GTi VWFpp (IU/dL) . | GTi VWFpp:Ag† . | CRP (mg/L) . |
|---|---|---|---|---|---|---|---|
| Diagnosis | 4 | 7 | 2 | <1 | 202 | >202 | 31 |
| RM1 | 147 | 135 | 92 | 116 | 227 | 1.96 | 6.9 |
| RL1 | <10 | <10 | 3 | <1 | 105 | >105 | 27 |
| Pre-DDAVP* | <10 | <10 | 5 | <1 | 129 | >129 | — |
| 1 hour post-DDAVP* | <10 | <10 | 7 | <1 | 172 | >172 | — |
| CR | 97 | 129 | 128 | 90 | 118 | 1.3 | 3.0 |
| NPP | — | — | — | 119 | 100 | 0.8 | — |
At the time of VWFpp ELISA assay by the GTI kit, VWF:Ag level was concurrently repeated with the GTI VWF:Ag ELISA assay kit, and GTI VWFpp:Ag is based on results obtained by the respective GTI assay kits.
CRP, C-reactive protein, normal range 0 to 10 mg/L; FVIII:C, factor VIII coagulant activity; NPP, normal pooled plasma; VWF:Act, VWF activity by immunoassay of GP1b binding domain of VWF; VWF:Ag, VWF antigen; VWFpp, VWF propeptide; VWFpp:Ag, ratio of VWFpp to VWF:Ag.
DDAVP testing performed during RL1.
Normal controls (n = 170) value; mean (standard deviation) = 1.2 (0.31).